CAS: 218777-23-2; 2-Pyridylzinc Bromide

专利信息

专利号:US-2025002518-A1
优先权日:2023-06-16
标 题 :Synthesis of heteroarynes and use thereof
发明人：MATTMILLER ROBERTS COURTNEY COLLEEN; HUMKE JENNA NICOLE; QUINLIVAN ANSEL ANNABEL; BELLI ROMAN GIANCARLO; KARGBO SALLU SO; PLASEK ERIN ELIZABETH
权利人:UNIV MINNESOTA
摘要:Disclosed herein are heterocyclic arynes and methods for preparing the same. Heteroarynes such as 5-membered O- or N-heterocyclic arynes have been considered inaccessible due to ring strain associated with the triple bond. The methods described herein demonstrate that these arynes can be successfully prepared through the utility of pi-backbonding from a transition metal. Synthetic utility of this method has been demonstrated by the facile synthesis and functionalization of heterocycles using these heteroaryne building blocks.

专利号:US-9040704-B2
优先权日:2011-08-12
标题:Fluorescent dyes with large stokes shifts
发明人：PIERS WARREN EDWARD; ARANEDA JUAN FELIPE
权利人:PIERS WARREN EDWARD; ARANEDA JUAN FELIPE; UTI LIMITED PARTNERSHIP
摘要:Herein are disclosed fluorescent dyes based around a framework for a ligand comprising a pyridyl group linked to a diaryl anilido unit. A variety of ligands based on this framework are disclosed. The ligands chelate to a BF 2 center to produce the fluorescent dye. The disclosed dyes combine longer Stokes shifts (approximately 100 nm) with increased quantum yields. They are also photostable in aqueous and organic solutions for several hours. These dyes may be used in the labeling of biomolecules for bioimaging and assays. Also disclosed are methods for the synthesis of these dyes.

专利号:WO-2009073246-A1
优先权日:2007-12-06
标 题 :Method for the synthesis of iridium (iii) complexes with sterically demanding ligands

专利号:US-6320049-B1
优先权日:1997-08-05
标题 :Alpha 1a adrenergic receptor antagonists
发明人：SIDLER DANIEL R; LARSEN ROBERT D; LI WENJIE
权利人:MERCK & CO INC
摘要:This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.

专利号:US-2009124805-A1
优先权日:2006-12-08
标题 :Method for synthesis of iriduim (iii) complexes with sterically demanding ligands

专利号:US-6255315-B1
优先权日:1997-06-18
标题:Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; SELNICK HAROLD G; BOCK MARK G
权利人:MERCK & CO INC
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha relductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.